Abstract:The authors regret that an error was made in the detail for affiliation c. The correct affiliation is: Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. The authors would like to apologise for any inconvenience caused. Re: Pathologic complete responses, long-term outcomes, and recurrence patterns in HER2-low vs. HER2-zero breast cancer after neoadjuvant chemotherapy: Several issues about HER2 expression and neoadjuvant chemotherapy in breast cancerEuropean Journal of CancerVol. 180PreviewWe followed with interest the report by Sora Kang et al. that pathological complete response (pCR) rate and disease-free survival (DFS) in patients with HER2-low as well as HER2-0 breast cancers who have undergone neoadjuvant chemotherapy [1]. There are many complex factors influencing condition of response and survival of breast cancer after neoadjuvant therapy by the changes of HER2 and hormone receptor (HR) status. We appreciated the authors' work in comparing the prognosis of patients with breast cancer after neoadjuvant chemotherapy in different HER2 status and providing new therapeutic ideas. Full-Text PDF

Correction to: The Effect of Postmastectomy Radiotherapy on Breast Cancer Patients After Neoadjuvant Chemotherapy by Molecular Subtype

The Effect of Postmastectomy Radiotherapy on Breast Cancer Patients After Neoadjuvant Chemotherapy by Molecular Subtype

Correction: An Experimental Analysis of the Molecular Effects of Trastuzumab (Herceptin) and Fulvestrant (Falsodex), as Single Agents or in Combination, on Human HR+/HER2+ Breast Cancer Cell Lines and Mouse Tumor Xenografts

Corrigendum: Neoadjuvant Tislelizumab Combined with Chemotherapy in Locally Advanced Oral or Oropharyngeal Squamous Cell Carcinoma: a Real-World Retrospective Study.

Corrigendum: Chemoresistance and Metastasis in Breast Cancer Molecular Mechanisms and Novel Clinical Strategies

Erratum to "BRCA1 subcellular localization regulated by PI3K signaling pathway in triple-negative breast cancer MDA-MB-231 cells and hormone-sensitive T47D cells"

Erratum: [Corrigendum] Survival outcomes in patients with T3‑4aN0M0 glottic laryngeal squamous cell carcinoma and evaluation of postoperative radiotherapy.

Correction To: Methylseleninic Acid Suppresses Breast Cancer Growth Via the JAK2/STAT3 Pathway

Impact Of Hormone Receptor Status And Distant Recurrence-Free Interval On Survival Benefits From Trastuzumab In Her2-Positive Metastatic Breast Cancer (Vol 7, 1134, 2017)

Corrigendum: Comparison of Clinical Outcomes Between Cone Beam CT-guided Thermal Ablation and Helical Tomotherapy in Pulmonary Metastases from Hepatocellular Carcinoma

Publisher Correction: Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy

Corrigendum: Long-term oncologic outcomes following breast cancer surgery in adolescents and young adults: a single-center retrospective analysis

Correction to: Impact of Ipsilateral Supraclavicular Lymph Node Dissection (ISLND) for Breast Cancer Patients and a Nomogram for Predicting Ipsilateral Supraclavicular Pathological Complete Response (ispCR)

Correction: Zhang et al. Clinical Management of Low Anterior Resection Syndrome: Review of the Current Diagnosis and Treatment. Cancers 2023, 15, 5011

Corrigendum to "re: Pathologic Complete Responses, Long-Term Outcomes, and Recurrence Patterns in HER2-low Vs. HER2-zero Breast Cancer after Neoadjuvant Chemotherapy: Several Issues about HER2 Expression and Neoadjuvant Chemotherapy in Breast Cancer" [eur J Cancer 180 (2023) 184-185].

Correction to: Efficacy and Safety of Supportive Care Biosimilars Among Cancer Patients: A Systematic Review and Meta‑Analysis

Corrigendum: Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis

Correction: Publisher Correction: Simultaneous Overactivation of Wnt/β-catenin and TGFβ Signalling by Mir-128-3p Confers Chemoresistance-Associated Metastasis in NSCLC

Correction to: Adjuvant Chemotherapy for Gastric Cancer Patients with Mismatch Repair Deficiency or Microsatellite Instability: Systematic Review and Meta-Analysis

Correction: Shi, H., et al. Arctigenin Attenuates Breast Cancer Progression through Decreasing GM-CSF/TSLP/STAT3/β-Catenin Signaling. Int. J. Mol. Sci. 2020, 21, 6357

Corrigendum to “ARMCX Family Gene Expression Analysis and Potential Prognostic Biomarkers for Prediction of Clinical Outcome in Patients with Gastric Carcinoma”